التفاصيل البيبلوغرافية
| العنوان: |
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities. |
| المؤلفون: |
Goodman, Rachel S., Jung, Seungyeon, Balko, Justin M., Johnson, Douglas B. |
| المصدر: |
Immunological Reviews; Sep2023, Vol. 318 Issue 1, p157-166, 10p |
| مصطلحات موضوعية: |
IMMUNE checkpoint inhibitors, BIOMARKERS, DRUG side effects, IPILIMUMAB, CANCER treatment, DRUG development |
| مستخلص: |
Summary: Immune checkpoint inhibitors have transformed cancer therapy, but their optimal use is still constrained by lack of response and toxicity. Biomarkers of response may facilitate drug development by allowing appropriate therapy selection and focusing clinical trial enrollment. However, aside from PD‐L1 staining in a subset of tumors and rarely mismatch repair deficiency, no biomarkers are routinely used in the clinic. In addition, severe toxicities may cause severe morbidity, therapy discontinuation, and even death. Here, we review the state of the field with a focus on our research in therapeutic biomarkers and toxicities from immune checkpoint inhibitors. [ABSTRACT FROM AUTHOR] |
|
Copyright of Immunological Reviews is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
